埃博拉感染母亲经单克隆抗体治疗后所生埃博拉阴性新生儿的病例系列
该病例系列报告2018-20年刚果民主共和国北基伍埃博拉疫情期间,两名埃博拉病毒阳性母亲在随机对照试验中接受研究性单克隆抗体治疗(mAB114或REGN-EB3)后分娩的活产新生儿。两名婴儿出生时埃博拉阴性,在埃博拉治疗中心进展良好,21天时仍为阴性且出院时健康。作者指出这是首批记录到的埃博拉阳性母亲所生出生时埃博拉阴性的新生儿,也是史上第三和第四例存活至婴儿期的患儿。
要点
- 埃博拉阳性母亲所生活产新生儿出生时埃博拉阴性,21天时仍阴性且出院健康。
- 两例新生儿及其母亲均接受了研究性单克隆抗体治疗(mAB114或REGN-EB3)。
- 病例数极少,无法就抗体治疗对新生儿的影响得出结论,需进一步研究。
核心结论
- 两例埃博拉病毒阳性母亲经单克隆抗体治疗后所生活产新生儿出生时埃博拉阴性,21天时仍阴性且出院时健康。
- 作者认为这是首批记录到的埃博拉阳性母亲所生出生时埃博拉阴性的新生儿,也是史上第三和第四例存活至婴儿期的患儿。
研究设计与样本
- 病例系列,报告2018-20年刚果民主共和国北基伍埃博拉疫情期间的两名活产新生儿。
- 两名新生儿及其埃博拉病毒阳性母亲作为随机对照试验(NCT03719586)的一部分接受了研究性单克隆抗体治疗(mAB114或REGN-EB3)。
主要发现
- 两名婴儿出生时埃博拉阴性,在埃博拉治疗中心进展良好。
- 两名新生儿在入院期间均未出现埃博拉病毒病证据,21天时埃博拉阴性,出院时保持健康。
临床怎么用
- 病例提示可考虑对所有埃博拉病毒阳性母亲的活产新生儿评估产后抗体治疗的可能性。
- 在低资源环境中,低出生体重婴儿存活率差,应重视充分的新生儿护理。
局限性
- 样本量极小(两例),无法就抗体治疗对新生儿的影响得出结论。
- 需要进一步研究调查抗体治疗对新生儿的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few fetuses survive childbirth when the mother is positive for Ebola virus, with almost all being miscarried or stillborn, or dying shortly after birth. Before 2019, only two infants had been reported surviving past 28 days, of whom one tested positive for Ebola virus and subsequently received experimental therapies. Little is understood regarding the care of surviving neonates born to Ebola virus-positive mothers in the postnatal period and how novel anti-Ebola virus therapies might affect neonatal outcomes. METHODS: In this case series, we report on two neonates liveborn during the 2018-20 North Kivu Ebola epidemic in the Democratic Republic of the Congo who, along with their Ebola virus-positive mothers, received investigational monoclonal antibody treatment (mAB114 or REGN-EB3) as part of a randomised controlled trial (NCT03719586). FINDINGS: Both infants were born Ebola-negative and progressed well while in the Ebola Treatment Centre. Neither neonate developed evidence of Ebola virus disease during the course of the admission, and both were Ebola-negative at 21 days and remained healthy at discharge. INTERPRETATION: To our knowledge these neonates are the first documented as Ebola virus-negative at birth after being born to Ebola virus-positive mothers, and only the third and fourth neonates ever documented to have survived into infancy. Although no conclusions can be drawn from this small case series, and further research is required to investigate the neonatal effects of antibody therapies, these cases warrant review regarding whether post-delivery antibody therapy should be considered for all liveborn neonates of Ebola virus-positive mothers. In the context of a low resource setting, where survival of low-birthweight infants is poor, these cases also highlight the importance of adequate neonatal care. FUNDING: None.
引用
- Ottoni MP, Ricciardone JD, Nadimpalli A, et al. Ebola-negative neonates born to Ebola-infected mothers after monoclonal antibody therapy: a case series. Lancet Child Adolesc Health. 2020. PMID: 33217357. doi:10.1016/S2352-4642(20)30278-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。